The Limits of AI in Clinical Trials and the Irreplaceable Role of Human Translators

Artificial intelligence has become inescapable — shaping everything from the way we write emails to how companies handle customer service. In many industries, it has delivered speed, efficiency, and scalability that were unimaginable just a decade ago. But clinical trials operate on a different plane. Here, precision is not optional; it underpins ethics, compliance, and, ultimately, patient safety. The stakes are far too high for shortcuts.

While technology can aid translators in various ways, the notion that machines can entirely supplant human expertise in a regulated, high-stakes field like life sciences, particularly in the unique challenges of clinical trials, is not just unrealistic. It’s risky.

The promises are persuasive:

• AI can translate millions of words in seconds.
• AI can replace entire teams of translators.
• AI can deliver faster, cheaper results.

In certain contexts, those claims hold weight. But in clinical research, translation is not about volume or cost alone. It is about accuracy, compliance, and trust.

A clinical trial protocol, an informed consent form, or a regulatory submission isn’t the same as a blog post or product description. These documents carry legal, ethical, and medical weight. A mistranslation doesn’t just create awkward phrasing; it can expose patients to misunderstanding, compromise the validity of study data, or delay access to urgently needed therapies.

The consequences are real. According to the Tufts Center for the Study of Drug Development, every month of delay in a clinical trial can cost sponsors between $600,000 and $8 million. Errors in translation that lead to rework or regulatory rejection can therefore have devastating financial and human impacts.

Believing that AI can “do it all” is more than misguided in this environment. It is potentially harmful.

Where AI Still Falls Short in Clinical Trials

AI systems have made remarkable progress in recent years, but they continue to fall short in the very areas that clinical trial translations demand most. In a regulated, high-stakes environment, these shortcomings can’t be overlooked:

Nuance and context

Medical terminology is rarely straightforward. A single word can change meaning depending on the disease area, study design, or regulatory framework. For instance, confusing a diagnostic marker with a prognostic marker can alter the interpretation of trial results. A 2023 study by Stanford researchers found that large language models made factual errors in 20–30% of medical question-answering tasks.

Regulatory phrasing

Agencies such as the FDA and EMA require exact wording in submissions. Approximation isn’t acceptable, yet AI often paraphrases instead of preserving critical regulatory language. Even minor deviations can lead to requests for clarification, or worse, rejected submissions. With the average cost of bringing a new drug to market now exceeding $2.3 billion, the financial impact of such delays is enormous.

Cultural sensitivity

Informed consent forms and patient-facing materials must go beyond accuracy to include empathy and cultural appropriateness. AI lacks the ability to assess tone or ensure reassurance is conveyed. This matters because clinical trial participation is already fragile: a recent analysis shows that up to 30% of patients drop out of trials, with communication barriers being a key factor.

Consistency across documents

A single clinical trial can generate hundreds of interlinked documents, from protocols to adverse event reports. Terminology must remain consistent across all of them, yet AI tools frequently introduce variations. Inconsistent translations can undermine trust among regulators and investigators and force costly rounds of revision.

In most industries, a mistranslation might cause confusion or minor reputational damage. In clinical trials, the consequences can be far more severe, including invalidated patient consent, compromised data integrity, regulatory rejection, costly delays, and, most critically, risks to patient safety.

This is where certified human translators and reviewers prove indispensable. They bring something AI cannot: judgment, cultural awareness, and a strong sense of ethical responsibility. In clinical trials, specialized translators are more than linguists. They are professionals with backgrounds in pharmacology, life sciences, and regulatory science.

It is this expertise that allows them to translate complex terminology with precision, ensure content meets country-specific compliance requirements, and adapt documentation so patients can understand their options and make truly informed decisions in their own language.

Why DTS Is Trusted for Clinical Trial Translations

At DTS Language Services, clinical trial translations are our specialty. With over 50 years of experience as an ISO-certified Language Services Provider, we deliver certified translations with guaranteed turnaround times, responsive project management, and a commitment to accuracy that clients can depend on.

We offer a range of services, including certified translations, transcription, on-demand interpreting, software localization, and multimedia solutions such as voiceover and subtitling. We support a wide range of sectors, including clinical trials, life sciences, biotechnology, medical devices, legal, manufacturing, healthcare, and medicine.

While human expertise drives our work, technology plays a vital supporting role. Centralized translation memory (TM) tools help maintain consistency across extensive, multi-phase studies, while increasing speed and efficiency. This dedication ensures that our clients receive translations they can trust, supporting successful trial outcomes, protecting patient safety, and ensuring data integrity is safeguarded.

Importantly, quality assurance is built into every step of our process: translators are carefully selected for their subject-matter expertise in clinical trial terminology and regulatory compliance, and every document is reviewed through multiple checkpoints guided by stringent standard operating procedures (SOPs).

Whether it’s an informed consent form, a clinical protocol, or a patient questionnaire, our focus is the same: precision, compliance, and cultural sensitivity. This dedication ensures that our clients receive translations they can trust, supporting successful trial outcomes, protecting patient safety, and safeguarding data integrity.

Where AI Ends and Human Responsibility Begins

AI and technology certainly have a place in clinical trial translation, but it’s a supportive one. The primary responsibility lies with experienced human translators who ensure compliance, protect patients, and uphold trust throughout the research process.

At DTS, we bring these elements together: technology improves and enhances efficiency and consistency, while human expertise guarantees accuracy, ethical responsibility, and cultural awareness. When patient safety and data integrity are at stake, translation requires more than algorithms. It needs people you can trust.